Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy

European Journal of Cancer

Volumn 49, Issue 1, 2013, Pages 115-120

  Sörenson, Sverre ^a,b   Fohlin, Helena ^a,b   Lindgren, Andrea ^a,b   Lindskog, Magnus ^c   Bergman, Bengt ^d,e   Sederholm, Christer ^b   Ek, Lars ^f   Lamberg, Kristina ^g   Clinchy, Birgitta ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Operations and Specialty Surgery Center   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Celecoxib; Chemotherapy; Non small cell lung cancer; Plasma VEGF; Survival

Indexed keywords

CARBOPLATIN; CELECOXIB; GEMCITABINE; NAVELBINE; PLACEBO; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOASSAY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871407592     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.032     Document Type: Article

References (20)

1. X. Liu, P. Yue, Z. Zhou, F.R. Khuri, and S.Y. Sun Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells J Natl Cancer Inst 96 2004 1769 1780 (Pubitemid 39654571)
2. J.L. Masferrer, K.M. Leahy, and A.T. Koki Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 60 2000 1306 1311 (Pubitemid 30151999)
3. A. Koch, B. Bergman, and E. Holmberg Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group Eur J Cancer 47 2011 1546 1555
4. H.J. Groen, H. Sietsma, and A. Vincent Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: The NVALT-4 Study J Clin Oncol 29 2011 4320 4326
5. J.R. Brown, and R.N. DuBois Cyclooxygenase as a target in lung cancer Clin Cancer Res 10 2004 4266s 4269s (Pubitemid 38812460)
6. K.M. Leahy, R.L. Ornberg, and Y. Wang Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo Cancer Res 62 2002 625 631 (Pubitemid 34126930)
7. M.K. Jones, H. Wang, and B.M. Peskar Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing Nat Med 5 1999 1418 1423
8. M. Tamura, Y. Ohta, and T. Kajita Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer Oncol Rep 8 2001 1097 1102 (Pubitemid 33758176)
9. W. Jelkmann Pitfalls in the measurement of circulating vascular endothelial growth factor Clin Chem 47 2001 617 623 (Pubitemid 32275802)
10. E. Hormbrey, P. Gillespie, and K. Turner A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 19 2002 651 663 (Pubitemid 36092260)
11. N.J. Webb, M.J. Bottomley, C.J. Watson, and P.E. Brenchley Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease Clin Sci (Lond) 94 1998 395 404 (Pubitemid 28176624)
12. M. Bonetti, and R.D. Gelber A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data Stat Med 19 2000 2595 2609
13. P. Royston, and W. Sauerbrei A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials Stat Med 23 2004 2509 2525 (Pubitemid 39149264)
14. E.O. Hanrahan, A.J. Ryan, and H. Mann Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer Clin Cancer Res 15 2009 3600 3609
15. E. Karl, Z. Zhang, and Z. Dong Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells Cell Death Differ 14 2007 1657 1666 (Pubitemid 47278851)
16. A. Catalano, L. Graciotti, and L. Rinaldi Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention Int J Cancer 109 2004 322 328 (Pubitemid 38252758)
17. J.C. Fisher, J.W. Gander, and M.J. Haley Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor Vasc Cell 3 2011 22
18. S. Kumar, R. Guleria, V. Singh, A.C. Bharti, A. Mohan, and B.C. Das Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer BMC Cancer 9 2009 421
19. E. Jantus-Lewintre, E. Sanmartin, and R. Sirera Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC Lung Cancer 74 2011 326 331
20. M.J. Pajares, J. Agorreta, and M. Larrayoz Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung J Clin Oncol 30 2012 1129 1136